The reduction in inventories by pharmaceutical customers has slowed down the packaging manufacturer Gerresheimer at the start of the year. This comes as no surprise, as many pharma and biotech.
(Reuters) -German packaging and medical equipment maker Gerresheimer expects diabetes and diet drugs to contribute 350 million euros ($376 million) of annual revenue by the 2026/27 financial year, CFO Bernd Metzner told Reuters after the company reported first-quarter results on Thursday. Obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound are administered by injector pens such as those made by Gerresheimer. Shares in Swiss rival Ypsomed surged in September after it announced a contract with Novo Nordisk for the "autoinjectors".
Diabetes and obesity drugs are expected to contribute 350 million euros: Gerresheimer financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
EQS-News: Gerresheimer AG / Key word(s): PersonnelGerresheimer AG: Guido Pickert to head up Investor Relations at Gerresheimer 05.12.2023 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Guido Pickert to head up Investor Relations at GerresheimerDuesseldorf, December 5, 2023. Gui.